HRP20210073T1 - Selektivni agonisti receptora glukagona s kelatnim dijelom za svrhe prikazivanja - Google Patents
Selektivni agonisti receptora glukagona s kelatnim dijelom za svrhe prikazivanja Download PDFInfo
- Publication number
- HRP20210073T1 HRP20210073T1 HRP20210073TT HRP20210073T HRP20210073T1 HR P20210073 T1 HRP20210073 T1 HR P20210073T1 HR P20210073T T HRP20210073T T HR P20210073TT HR P20210073 T HRP20210073 T HR P20210073T HR P20210073 T1 HRP20210073 T1 HR P20210073T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- do3a
- cys
- acid selected
- lys
- Prior art date
Links
- 108010063919 Glucagon Receptors Proteins 0.000 title claims 5
- 102100040890 Glucagon receptor Human genes 0.000 title claims 5
- 238000003384 imaging method Methods 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000000539 amino acid group Chemical group 0.000 claims 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- HHLZCENAOIROSL-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OC(=O)CN1CCNCCN(CC(O)=O)CCN(CC(O)=O)CC1 HHLZCENAOIROSL-UHFFFAOYSA-N 0.000 claims 4
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims 4
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 4
- 150000004696 coordination complex Chemical class 0.000 claims 4
- 229910021645 metal ion Inorganic materials 0.000 claims 4
- 238000012800 visualization Methods 0.000 claims 4
- 150000002500 ions Chemical class 0.000 claims 3
- 239000002184 metal Substances 0.000 claims 3
- 229910018085 Al-F Inorganic materials 0.000 claims 2
- 229910018179 Al—F Inorganic materials 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 150000003951 lactams Chemical class 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 claims 1
- NYCRCTMDYITATC-UHFFFAOYSA-N 2-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1F NYCRCTMDYITATC-UHFFFAOYSA-N 0.000 claims 1
- 241000024188 Andala Species 0.000 claims 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 1
- 229940123232 Glucagon receptor agonist Drugs 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 1
- NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (15)
1. Peptidni spoj formule (I):
[image]
naznačen time što
X2 predstavlja aminokiselinu odabranu između Ser i d-Ser,
X3 predstavlja aminokiselinu odabranu između Gln i His,
X7 predstavlja aminokiselinu odabranu između Thr i Aib,
X10 predstavlja aminokiselinski ostatak odabran između Tyr, Leu, Val, Ile, Phe, fenilglicina, Thr, 2-fluorofenilalanina, Cikloheksilglicina i terc-leucina,
X12 predstavlja aminokiselinu odabranu između Lys, Arg i Cys (VS-DO3A),
X13 predstavlja aminokiselinu odabranu između Gln, Tyr i Cys (VS-DO3A),
X14 predstavlja aminokiselinski ostatak odabran između Leu, Nle i Cys (VS-DO3A),
X15 predstavlja aminokiselinu odabranu između Glu i Asp,
X16 predstavlja aminokiselinu odabranu između Ser, Glu, Aib i Cys (VS-DO3A),
X17 predstavlja aminokiselinu odabranu između Arg, Gln, Lys, Ala i Cys (VS-DO3A),
X18 predstavlja aminokiselinu odabranu između Arg, Lys i Ala,
X20 predstavlja aminokiselinu odabranu između Gln, Glu, Aib, Lys i Cys (VS-DO3A),
ako je X16 Glu, a X20 Lys, bočni lanci X16 i X20 mogu formirati ciklički prsten preko laktama,
X21 predstavlja aminokiselinski ostatak odabran između Asp i Glu,
X28 predstavlja aminokiselinu odabranu između Ala i β-Ala,
X29 predstavlja aminokiselinski ostatak odabran između Gly i Thr,
X32 predstavlja aminokiselinu odabranu između Glu i Ser,
X40 predstavlja aminokiselinu odabranu između Cys (VS-DO3A), Cys (VS-NO2A), Cys (mal-DOTA), Cys (mal-NOTA), Cys (mal-NODAGA), Lys (DOTA), Lys (NOTA), Lys (PEG-DOTA) i Lys (VS-DO3A) ili X40 mogu biti odsutni ako jedna od aminokiselina X12, X13, X14, X16, X17 ili X20 je Cys (VS-DO3A),
pri čemu DOTA, NOTA, DO3A, NO2A ili NODAGA mogu biti neopterećeni ili opterećeni metalnim ionom odabranim između Gd3+, Ga3+, Cu2+, (Al-F)2+, Y3+, Tc3+, In3+, Lu3+ i Re3+,
R1 predstavlja OH ili NH2;
i pri čemu je spoj agonist receptora glukagona;
ili metalni kompleks ili njegova sol ili solvat.
2. Spoj formule (I) prema zahtjevu 1, naznačen time što
X2 predstavlja aminokiselinu odabranu između Ser i d-Ser,
X3 je Gln,
X7 predstavlja aminokiselinu odabranu između Thr i Aib,
X10 predstavlja aminokiselinski ostatak odabran između Tyr, Leu, Ile, X12 je Lys,
X13 je Gln,
X14 predstavlja aminokiselinski ostatak odabran između Leu i Nle, X15 predstavlja aminokiselinu odabranu između Glu i Asp,
X16 predstavlja aminokiselinu odabranu između Ser i Glu,
X17 predstavlja aminokiselinu odabranu između Arg i Gln,
X18 je Arg,
X20 predstavlja aminokiselinu odabranu između Gln i Lys,
ako je X16 Glu i X20 Lys, bočni lanci X16 i X20 mogu formirati ciklički prsten preko laktama,
X21 predstavlja aminokiselinski ostatak odabran između Asp i Glu, X28 je Ala,
X29 predstavlja aminokiselinski ostatak odabran između Gly i Thr, X32 je Glu,
X40 je Cys (VS-DO3A),
pri čemu DO3A može biti neopterećen ili opterećen metalnim ionom odabranim između Gd3+, Ga3+, Cu2+, (Al-F)2+, Y3+, Tc3+, In3+, Lu3+ i Re3+,
R1 predstavlja OH ili NH2;
ili metalni kompleks ili njegova sol ili solvat.
3. Spoj formule (I) prema zahtjevu 1, odabran između spojeva SEQ ID NO: 3 - 90, kao i metalni kompleks, njegove soli ili solvati.
4. Spoj formule (I) prema bilo kojem od zahtjeva 1 do 3, odabran između spojeva SEQ ID NO: 6, 8, 13, 14, 35, 36, 49, 50, 60, 61, 79, 80, 85 i 86, kao i metalni kompleks, njegove soli ili solvati.
5. Spoj formule (I) prema bilo kojem od zahtjeva 1 do 4, naznačen time što su DOTA, NOTA, DO3A, NO2A ili NODAGA opterećeni (i) metalnim ionom Ga3+, ili (ii) metalnim ionom Gd3+.
6. Spoj formule (I) prema bilo kojem od zahtjeva 1 do 4, naznačen time što su DOTA, NOTA, DO3A, NO2A ili NODAGA opterećeni (i) metalnim radionukleotidnim ionom (Cu-64)2+, (Ga-68)3+, (Al-F-18)2+, (Y-86)3+, (ii) s metalnim radionukleotidnim ionom (Ga-67)3+, (Tc-99m)3+, (In-111)3+ ili (iii) s metalnim radionukleotidnim ionom odabranim od (Cu-67)2+, (Y-90)3+, (In-111)3+, (Lu-177)3+, (Re-186)3+ i (Re-188)3+.
7. Farmaceutski pripravak koji sadrži najmanje jedan spoj prema bilo kojem od zahtjeva 1 - 6 ili fiziološki prihvatljivu sol ili solvat bilo kojeg od njih.
8. Spoj prema bilo kojem od zahtjeva 1-6 koji je prisutan kao aktivno sredstvo u farmaceutskom pripravku, zajedno s najmanje jednim farmaceutski prihvatljivim nosačem.
9. Spoj prema bilo kojem od zahtjeva 1 - 6 za vizualizaciju receptora glukagona u živim subjektima i relevantnim tkivima.
10. Spoj prema bilo kojem od zahtjeva 1 - 6 za uporabu u medicini, posebno u humanoj medicini.
11. Spoj prema zahtjevu 5 (ii) za vizualizaciju receptora glukagona u živim subjektima i relevantnim tkivima pomoću MRI.
12. Spoj prema zahtjevu 6 (i) za vizualizaciju receptora glukagona u živim subjektima i relevantnim tkivima pomoću PET-a.
13. Spoj prema zahtjevu 6 (ii) za vizualizaciju receptora glukagona u živim subjektima i relevantnim tkivima pomoću SPECT-a.
14. Spoj prema zahtjevu 6 (iii) za uporabu u radioterapiji.
15. Spoj prema bilo kojem od zahtjeva 1 do 6 za uporabu u liječenju hipoglikemije, povećanja razine glukoze u krvi ili kao dodatna terapija inzulinom, pri čemu se komponenta posebno daje parenteralno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15307000 | 2015-12-14 | ||
| PCT/EP2016/080553 WO2017102613A1 (en) | 2015-12-14 | 2016-12-12 | Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes |
| EP16819291.2A EP3389697B1 (en) | 2015-12-14 | 2016-12-12 | Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210073T1 true HRP20210073T1 (hr) | 2021-04-30 |
Family
ID=55129466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210073TT HRP20210073T1 (hr) | 2015-12-14 | 2021-01-14 | Selektivni agonisti receptora glukagona s kelatnim dijelom za svrhe prikazivanja |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11046743B2 (hr) |
| EP (1) | EP3389697B1 (hr) |
| JP (1) | JP6986516B2 (hr) |
| KR (1) | KR20180086270A (hr) |
| CN (1) | CN108697767B (hr) |
| AU (1) | AU2016372245B2 (hr) |
| BR (1) | BR112018011892A2 (hr) |
| CA (1) | CA3008052C (hr) |
| DK (1) | DK3389697T3 (hr) |
| ES (1) | ES2846023T3 (hr) |
| HR (1) | HRP20210073T1 (hr) |
| HU (1) | HUE053079T2 (hr) |
| IL (1) | IL259961A (hr) |
| LT (1) | LT3389697T (hr) |
| MX (1) | MX2018007323A (hr) |
| PL (1) | PL3389697T3 (hr) |
| PT (1) | PT3389697T (hr) |
| RU (1) | RU2018125958A (hr) |
| SG (1) | SG11201804993RA (hr) |
| SI (1) | SI3389697T1 (hr) |
| WO (1) | WO2017102613A1 (hr) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004043153B4 (de) | 2004-09-03 | 2013-11-21 | Philipps-Universität Marburg | Erfindung betreffend GLP-1 und Exendin |
| CN101282991A (zh) * | 2005-05-26 | 2008-10-08 | 布里斯托尔-迈尔斯斯奎布公司 | N-端修饰的胰高血糖素样肽-1受体调节剂 |
| WO2007139589A1 (en) | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
| UA116217C2 (uk) * | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| CN104870009B (zh) * | 2012-12-21 | 2021-05-18 | 赛诺菲 | 官能化的毒蜥外泌肽-4衍生物 |
| US9932381B2 (en) * | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
-
2016
- 2016-12-12 MX MX2018007323A patent/MX2018007323A/es unknown
- 2016-12-12 BR BR112018011892-3A patent/BR112018011892A2/pt not_active Application Discontinuation
- 2016-12-12 DK DK16819291.2T patent/DK3389697T3/da active
- 2016-12-12 ES ES16819291T patent/ES2846023T3/es active Active
- 2016-12-12 PT PT168192912T patent/PT3389697T/pt unknown
- 2016-12-12 CA CA3008052A patent/CA3008052C/en active Active
- 2016-12-12 HU HUE16819291A patent/HUE053079T2/hu unknown
- 2016-12-12 PL PL16819291T patent/PL3389697T3/pl unknown
- 2016-12-12 WO PCT/EP2016/080553 patent/WO2017102613A1/en active Application Filing
- 2016-12-12 AU AU2016372245A patent/AU2016372245B2/en active Active
- 2016-12-12 JP JP2018549616A patent/JP6986516B2/ja active Active
- 2016-12-12 SG SG11201804993RA patent/SG11201804993RA/en unknown
- 2016-12-12 SI SI201631056T patent/SI3389697T1/sl unknown
- 2016-12-12 KR KR1020187019959A patent/KR20180086270A/ko not_active Application Discontinuation
- 2016-12-12 LT LTEP16819291.2T patent/LT3389697T/lt unknown
- 2016-12-12 CN CN201680081731.0A patent/CN108697767B/zh active Active
- 2016-12-12 EP EP16819291.2A patent/EP3389697B1/en active Active
- 2016-12-12 US US16/061,421 patent/US11046743B2/en active Active
- 2016-12-12 RU RU2018125958A patent/RU2018125958A/ru not_active Application Discontinuation
-
2018
- 2018-06-12 IL IL259961A patent/IL259961A/en unknown
-
2021
- 2021-01-14 HR HRP20210073TT patent/HRP20210073T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3389697B1 (en) | 2020-12-16 |
| PL3389697T3 (pl) | 2021-04-19 |
| JP2019508480A (ja) | 2019-03-28 |
| ES2846023T3 (es) | 2021-07-28 |
| SI3389697T1 (sl) | 2021-02-26 |
| WO2017102613A1 (en) | 2017-06-22 |
| AU2016372245B2 (en) | 2020-07-16 |
| LT3389697T (lt) | 2021-02-10 |
| SG11201804993RA (en) | 2018-07-30 |
| CN108697767A (zh) | 2018-10-23 |
| RU2018125958A3 (hr) | 2020-06-09 |
| CA3008052A1 (en) | 2017-06-22 |
| PT3389697T (pt) | 2021-01-22 |
| DK3389697T3 (da) | 2021-01-11 |
| US20200262885A1 (en) | 2020-08-20 |
| US11046743B2 (en) | 2021-06-29 |
| BR112018011892A2 (pt) | 2018-12-04 |
| RU2018125958A (ru) | 2020-01-20 |
| CA3008052C (en) | 2024-01-02 |
| HUE053079T2 (hu) | 2021-06-28 |
| CN108697767B (zh) | 2022-04-15 |
| MX2018007323A (es) | 2019-01-10 |
| IL259961A (en) | 2018-07-31 |
| KR20180086270A (ko) | 2018-07-30 |
| JP6986516B2 (ja) | 2021-12-22 |
| AU2016372245A1 (en) | 2018-07-26 |
| EP3389697A1 (en) | 2018-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Virgolini et al. | 111In-and 90Y-DOTA-lanreotide: results and implications of the MAURITIUS trial | |
| Parry et al. | In vitro and in vivo evaluation of 64Cu-labeled DOTA− linker− bombesin (7− 14) analogues containing different amino acid linker moieties | |
| CN106573959B (zh) | 修饰的环五肽及其用途 | |
| Varasteh et al. | The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26 | |
| RU2594167C2 (ru) | Композиции пептидных радиоактивных индикаторов | |
| CA2972058C (en) | Compositions and methods for imaging cancer | |
| Sparr et al. | Syntheses, Receptor Bindings, in vitro and in vivo Stabilities and Biodistributions of DOTA‐Neurotensin (8–13) Derivatives Containing β‐Amino Acid Residues–A Lesson about the Importance of Animal Experiments | |
| Nock et al. | Novel bifunctional DATA chelator for quick access to site-directed PET 68 Ga-radiotracers: preclinical proof-of-principle with [Tyr 3] octreotide | |
| ES2676184T3 (es) | Composición para su uso en un método para la selección de cánceres | |
| HRP20210073T1 (hr) | Selektivni agonisti receptora glukagona s kelatnim dijelom za svrhe prikazivanja | |
| JP7502801B2 (ja) | ガストリン放出ペプチド受容体（ｇｒｐｒ）のインビボイメージングおよびｇｒｐｒ関連障害の治療のための放射性標識ボンベシン由来化合物 | |
| Zheng et al. | Comparison of biological properties of 111In-labeled dimeric cyclic RGD peptides | |
| JP6824888B2 (ja) | 筋肉の疾患および障害を治療するための方法および組成物 | |
| Karachaliou et al. | Specific in vitro binding of a new 99mTc-radiolabeled derivative of the C-terminal decapeptide of prothymosin alpha on human neutrophils | |
| US9234007B2 (en) | RGD mimetic γ-AApeptides and methods of use | |
| Brogsitter et al. | Twins in spirit: DOTATATE and high-affinity DOTATATE | |
| Ding et al. | A human GRPr‐transfected Ace‐1 canine prostate cancer model in mice | |
| RU2013113677A (ru) | Визуализирующие апоптоз агенты на основе лантибиотических пептидов | |
| Sadeghzadeh et al. | Radiochemical Evaluation of New 99mTc-labelled Bombesin Derivatives with Tripeptidic (Ser-Ser-Ser) and (Gly-Gly-Gly) Spacer for Targeting GRP Receptor Positive-tumors | |
| JP4759508B2 (ja) | ペプチドの水溶性及び金属標識効率を改善した医療用組成物及び該ペプチドが金属標識された医療用製剤 | |
| US10420850B2 (en) | Method of imaging with a chelating agent | |
| نورالله صادق زاده et al. | Radiochemical Evaluation of New 99 mTc-labelled Bombesin Derivatives with Tripeptidic (Ser-Ser-Ser) and (Gly-Gly-Gly) Spacer for Targeting GRP Receptor Positive-tumors. | |
| Lindeberg et al. | The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26 |